NCT05429866 - Immunological Variables Associated to ICI Toxicity in Cancer Patients | Biotech Hunter

Enrollment

441

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

December 1, 2024

Conditions

Breast CancerMelanomaNon Small Cell Lung CancerNon-melanoma Skin CancerGastrointestinal CancerHead and Neck CancerRenal Cell CarcinomaSmall Cell Lung CancerMesothelioma, MalignantBladder CancerMerkel Cell CarcinomaHepatocellular CarcinomaMSI-H Colorectal Cancer

Interventions

DRUG

Checkpoint Blockade, Immune

Immune checkpoint blockade drugs target the immune system by blocking control pathways regulating anti-tumor immunity and thereby reinvigorate their activities against cancer.

Trial Locations (1)

1070

RECRUITING

Institut Jules Bordet, Brussels